Dr. Bartosz Chmielowski, MD
Claim this profileUCLA
Expert in Melanoma
Studies Skin Cancer
17 reported clinical trials
31 drugs studied
Area of expertise
1Melanoma
Global LeaderStage IV
BRAF positive
Stage III
2Skin Cancer
Stage IV
BRAF positive
Stage III
Affiliated Hospitals
Clinical Trials Bartosz Chmielowski, MD is currently running
APG-115 + Pembrolizumab
for Skin Cancer
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Recruiting1 award Phase 1 & 213 criteria
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 Tablet and Food Effect Pharmacokinetic (PK) Substudy will assess the PK profile of IDE196 tablet and evaluate the effects of food on the PK profile of IDE196 tablet Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.
Recruiting1 award Phase 1 & 29 criteria
More about Bartosz Chmielowski, MD
Clinical Trial Related2 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Bartosz Chmielowski, MD has experience with
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Dacarbazine
- RP1
- ITIL-168
Breakdown of trials Bartosz Chmielowski, MD has run
Melanoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Bartosz Chmielowski, MD specialize in?
Bartosz Chmielowski, MD focuses on Melanoma and Skin Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are BRAF positive.
Is Bartosz Chmielowski, MD currently recruiting for clinical trials?
Yes, Bartosz Chmielowski, MD is currently recruiting for 5 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Bartosz Chmielowski, MD has studied deeply?
Yes, Bartosz Chmielowski, MD has studied treatments such as Nivolumab, Pembrolizumab, Ipilimumab.
What is the best way to schedule an appointment with Bartosz Chmielowski, MD?
Apply for one of the trials that Bartosz Chmielowski, MD is conducting.
What is the office address of Bartosz Chmielowski, MD?
The office of Bartosz Chmielowski, MD is located at: UCLA, Los Angeles, California 90095 United States. This is the address for their practice at the UCLA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.